# Campaign Launched in Memory of Mum Who Helped Change UK Medical Cannabis Law > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/nhs-access-barriers-medical-cannabis-pediatric-epilepsy/ > **Published:** 2026-03-05T10:45:25-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T12:00:49-04:00 > **Clinical Summary:** Explore NHS access barriers medical cannabis for pediatric epilepsy and the campaign to improve treatment options for drug-resistant cases in the UK. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyPolicyPediatricsCBD Why This Matters Clinicians treating pediatric drug-resistant epilepsy need to understand current NHS access barriers to [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/), as evidence-based cannabinoid therapies have demonstrated efficacy in this population but remain unavailable through standard channels. This campaign highlights the gap between regulatory approval and clinical availability, directly affecting treatment options that clinicians can offer families of affected children. Awareness of these access limitations enables clinicians to better counsel patients on available alternatives and advocate for policy changes that could expand evidence-based treatment options. Clinical Summary This campaign addresses a significant access gap in UK [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) practice, highlighting that children with drug-resistant epilepsy remain unable to obtain cannabis-based medicinal products through the NHS despite the 2018 legal change permitting specialist prescribing. The regulatory framework allows physician-led cannabis prescriptions for specific conditions including refractory epilepsy, yet NHS funding barriers and stringent access criteria have left eligible pediatric patients without realistic pathways to this evidence-supported treatment. The campaign advocates for government funding and streamlined NHS protocols to enable clinicians to prescribe cannabis medicines to children for whom conventional anticonvulsants have failed, a population with substantial unmet medical need and documented clinical benefit in some cases. For practitioners treating drug-resistant epilepsy in pediatric populations, this reflects the persistent gap between legal authorization and practical access, requiring awareness of private prescribing pathways and engagement with local NHS commissioning discussions. Clinicians should understand current NHS [cannabis prescribing](https://cedclinic.com/addressing-cannabis-education-gap-clinical-care/) policies in their regions and discuss both available routes and ongoing advocacy efforts with families of affected children. Dr. Caplan’s Take “We’ve known for over a decade that cannabidiol can be genuinely life-changing for children with severe, intractable seizure disorders, yet the gap between clinical evidence and actual patient access remains a profound failure of healthcare systems on both sides of the Atlantic. When families have to fight bureaucracies or leave their countries to access a medicine that could stop their child’s seizures, we’ve stopped practicing medicine and started practicing politics instead.” Clinical Perspective While the UK’s 2018 decision to permit medical cannabis prescriptions for certain conditions including drug-resistant epilepsy represented important regulatory progress, implementation gaps have created a two-tiered access system where many eligible patients cannot obtain treatment through NHS channels. The clinical evidence base for cannabinoid efficacy in pediatric epilepsy, particularly for conditions like [Dravet syndrome](https://cedclinic.com/cannabidiol-for-epilepsy-treatment-rare-forms/), is genuine but remains incomplete, with ongoing questions about optimal dosing, long-term safety profiles, and patient selection criteria that complicate straightforward clinical guidance. Clinicians face the difficult position of having patients who may benefit from cannabis-based medicines yet lack accessible pathways to prescribe them within standard care, while private options remain prohibitively expensive for most families. Advocacy efforts highlighting individual patient stories are understandable but should be accompanied by continued investment in rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and transparent NHS commissioning frameworks that balance compassionate access with evidence standards. For practitioners managing children 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Campaign+Launched+in+Memory+of+Mum+Who+Helped+Change+UK+Medical+Cannabis+Law+%40drcaplan&url=https%3A%2F%2Fcannabishealthnews.co.uk%2F2026%2F03%2F05%2Fcampaign-launched-in-memory-of-mum-who-helped-change-uk-medical-cannabis-law%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcannabishealthnews.co.uk%2F2026%2F03%2F05%2Fcampaign-launched-in-memory-of-mum-who-helped-change-uk-medical-cannabis-law%2F) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Campaign+Launched+in+Memory+of+Mum+Who+Helped+Change+UK+Medical+Cannabis+Law+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fcannabishealthnews.co.uk%2F2026%2F03%2F05%2Fcampaign-launched-in-memory-of-mum-who-helped-change-uk-medical-cannabis-law%2F) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://cannabishealthnews.co.uk/2026/03/05/campaign-launched-in-memory-of-mum-who-helped-change-uk-medical-cannabis-law/](https://cannabishealthnews.co.uk/2026/03/05/campaign-launched-in-memory-of-mum-who-helped-change-uk-medical-cannabis-law/) Further Reading Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Evidence Watch[`Cannabinoid Clinical Trials: CBD Cortical Excitability Study`](https://cedclinic.com/cannabidiol-lacks-intrinsic-anti-epileptic-properties-trial/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Current status of medical cannabis in the UK – Government](https://cedclinic.com/uk-medical-cannabis-access-status/) An overview of the UK government's stance and regulatory framework on medical cannabis, highlighting ongoing challenges and developments. [Learn More](https://cedclinic.com/uk-medical-cannabis-access-status/) [Oliver's Law: Campaign Calls for Changes to Medical Cannabis Prescribing in Psychiatric Conditions](https://cedclinic.com/psychiatric-cannabis-prescribing-guidelines-olivers-law/) A campaign advocating for expanded medical [cannabis prescribing](https://cedclinic.com/addressing-cannabis-education-gap-clinical-care/) rights, reflecting broader efforts to improve patient access across conditions. [Read Campaign Details](https://cedclinic.com/psychiatric-cannabis-prescribing-guidelines-olivers-law/) [The Man Who Treats Sick Children with Cannabis, No Matter the Cost – Esquire](https://cedclinic.com/pediatric-cannabis-compassionate-use-treatment-insights/) A profile highlighting the challenges and dedication involved in providing cannabis treatment to children with severe conditions. [Explore Story](https://cedclinic.com/pediatric-cannabis-compassionate-use-treatment-insights/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).